CA-NETAPP

10.4.2024 19:01:45 CEST | Business Wire | Press release

NetApp Partners with Google Cloud to Maximize Flexibility for Cloud Data Storage

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced an expansion of its partnership with Google Cloud to make it easier for organizations to leverage their data for generative AI (GenAI) and other hybrid cloud workloads. NetApp and Google Cloud are announcing the Flex service level for Google Cloud NetApp Volumes which supports storage volumes of nearly any size. NetApp is also releasing a preview of its GenAI toolkit reference architecture for retrieval-augmented generation (RAG) operations using Google Cloud Vertex AI platform.

More Flexible Data Storage Options for Google Cloud NetApp Volumes

Google Cloud and NetApp are announcing a new service level for NetApp Volumes called Flex that gives customers more granular control to adapt their storage and performance to match the exact needs of their cloud workloads.

“Increasing demand for data-intensive applications and insights has reinforced the need for a new approach to unified data storage that gives organizations the agility to move and store data wherever it is needed at any point in time,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “By extending our collaboration with Google Cloud, we’re delivering a flexible form factor that can be run on existing infrastructure across Google Cloud system without any tradeoffs to enterprise data management capabilities.”

With the addition of Flex, NetApp Volumes customers can choose from four service levels to leverage a fully managed file service built on NetApp ONTAP^TM and operated by Google Cloud, including:

Standard: highly available, general-purpose storage with advanced data management capabilities and 16MiB/sec per TiB of performance, which is recommended to support workloads such as file shares, virtual machines (VMs), and DevTest environments.
Premium: highly available, high-performance storage with advanced data management capabilities and 64MiB/sec per TiB of performance, which is recommended for file shares, VMs, and databases.
Extreme: highly available, low-latency, high-throughput storage with advanced data management capabilities and 128MiB/sec per TiB of performance, which is recommended for Online Transaction Processing (OLTP) high-performance databases and low-latency applications.
Flex: highly available storage volumes with scalability from one GiB to 100TiB and up to one GiB/s of performance depending on the size of the underlying storage pool. This adaptable service level can support a wide variety of use cases, including AI.

“Google Cloud NetApp Volumes remains a critical component of every enterprise’s digital transformation strategy,” said Sameet Agarwal, GM/VP, Google Cloud Storage at Google Cloud. “Utilizing Google Cloud technologies, NetApp Volumes will power new capabilities that can improve how businesses operate and create real-world value for their organizations.”

The Flex service level will be generally available by Q2 2024 across 15 Google Cloud regions, expanding to the other Google Cloud regions by the end of 2024.

Unlocking Enterprise Data for Generative AI in Google Cloud

NetApp is also releasing a preview of its GenAI toolkit with support for NetApp Volumes. This offering, along with the accompanying reference architecture, speeds the implementation of RAG operations while enabling secure, consistent, and automated workflows that securely connect data stored in NetApp Volumes with Google Cloud Vertex AI platform. The result is a greater ability to generate unique, high-quality, and ultra-relevant insights and automations.

“As the intelligent data infrastructure company, we have unmatched capabilities to support data classification, tagging, mobility, and cloning for data wherever it lives so our customers can run efficient and secure AI data pipelines,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “Building on our partnership with Google Cloud to streamline RAG enables customers to tap into market-leading AI services and models to generate a unique competitive advantage.”

The NetApp GenAI toolkit helps optimize RAG processes with unique capabilities, including:

Common data footprint everywhere: NetApp ONTAP allows customers to easily include data from any environment to power their RAG efforts with common operational processes while reducing risk, cost, and time to results.
Automated classification and tagging: NetApp’s BlueXP classification service automatically tags data to support streamlined data cleansing for both the ingest and inferencing phases of the data pipeline, ensuring that the right data is used for queries and that sensitive data is not exposed to the model out of policy.
Fast, scalable snapshots: ONTAP Snapshot delivers near-instant creation of space-efficient, in-place copies of vector stores and databases, allowing immediate roll back to a previous version if data is corrupted or forward if point-in-time analysis is needed.
Real-time cloning at scale: ONTAP FlexClone technology can create instant clones of vector index stores to safely make uniquely relevant data instantly available for different queries for different users, without impacting the core production data.

“GenAI is a tidal wave of opportunity for the companies that can effectively apply their data to their industry,” said Miles Ward, CTO at SADA, An Insight Company. “At SADA we are fired up about pairing our extensive expertise with NetApp and Vertex AI to help customers accelerate their AI journeys. Why generate uninformed chats when you could generate unique, specific, relevant insights?”

The GenAI toolkit will be available as a public preview within the second half of 2024.

To learn more about the Flex service level for NetApp Volumes or the GenAI toolkit reference architecture for Vertex AI, visit the NetApp booth #1231 at the Google Cloud Next 2024 conference running from April 9-11 at Mandalay Bay in Las Vegas.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410415954/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom